Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep 1;2(5):773-778.
doi: 10.3892/ol.2011.334. Epub 2011 Jul 4.

Synergistic antitumor efficacy by combining adriamycin with recombinant human endostatin in an osteosarcoma model

Hairong Xu  1 , Xiaohui Niu, Qing Zhang, Lin Hao, Yi Ding, Weifeng Liu, Lu Yao
Affiliations

Synergistic antitumor efficacy by combining adriamycin with recombinant human endostatin in an osteosarcoma model

Hairong Xu et al. Oncol Lett. .

Abstract

In the last 15 years, chemotherapy-based therapeutic regimens for the treatment of osteosarcoma have failed to demonstrate improved survival rates. Novel approaches, including targeted therapy and antiangiogenic therapy, may provide new methods for the treatment of osteosarcoma, one of the most deadly malignant diseases. In the present study, the therapeutic efficacy of an endogenous angiogenesis inhibitor, endostatin, was tested in combination with the chemotherapeutic agent, adriamycin. BALB/c mice, aged 4-6 weeks were fed animal chow and had access to water ad libitum. The mice were divided into groups and injected with tumor cells. Immunohistochemical staining was performed to identify the microvessel density. The TUNEL technique was also used to determine the apoptotic index. The combination of endostatin and adriamycin produced marked synergistic antitumor activity in a mouse osteosarcoma model. These findings provide new guidelines for designing future clinical trials and for the application of currently available clinical drugs (endostatin has been approved for clinical use) in the treatment of osteosarcoma.

PubMed Disclaimer

Figures

Table 1
Table 1. Tumor weight and tumor inhibition rate of various rh‑endostatin treatment groups.
Table 2
Table 2. Combination treatment of rh‑endostatin with adriamycin FTWa relative to controls.
Table 3
Table 3. MVD of various treatment groups.
Figure 1
Figure 1. (A) Tissue stained with hematoxylin and eosin is shown and the nuclear pleomorphism of malignant tumor feature is evident (arrow). (B) Intratumoral vascular endothelium cells were stained by rabbit anti-Fac VIII (arrow). Tumor tissue with (D) high-dose rh-endostatin treatment alone showed fewer new vascular endothelium cells than the (C) control. (B-D) were counterstained with hematoxylin.
Table 4
Table 4. AI of various treatment groups.
Figure 2
Figure 2. Combination treatment of high-dose (B) rh‑endostatin and adriamycin showed more apoptotic tumor cells than the (A) control. (C) and (D) show that apoptotic foci were often concentrated within the perivascular areas in the combination treatment groups
See this image and copyright information in PMC

References

    1. Bielack SS, Carrle D, Hardes J, Schuck A and Paulussen M: Bone tumors in adolescents and young adults. Curr Treat Options Oncol 9: 67-80, 2008. - PubMed
    1. Link MP, Goorin AM, Miser AW, et al: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314: 1600-1606, 1986. - PubMed
    1. Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M and Picci P: Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer 41: 2836-2845, 2005. - PubMed
    1. Chou AJ, Geller DS and Gorlick R: Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 10: 315-327, 2008. - PubMed
    1. Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C and Huvos AG: Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 43: 2163-2177, 1979. - PubMed

LinkOut - more resources